IMPACT THERAP-B(07630),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

07630 IMPACT THERAP-B

Trading 06-25 15:56:34

35.260

-0.800

-2.22%

High35.800	Low34.540	Vol338.60K
Open35.800	D1 Closing36.060	Amplitude3.49%
Mkt Cap9.96B	Tradable Cap9.96B	Total Shares282.46M
T/O11.87M	T/O Rate0.12%	Tradable Shares282.46M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"07630","market":"HK","secType":"STK","nameCN":"IMPACT THERAP-B","latestPrice":35.26,"timestamp":1782374168465,"preClose":36.06,"halted":0,"volume":338600,"delay":0,"changeRate":-0.022185246810870887,"floatShares":282461530,"shares":282461530,"eps":-1.440772,"marketStatus":"Trading","change":-0.8,"latestTime":"06-25 15:56:34","open":35.8,"high":35.8,"low":34.54,"amount":11868126,"amplitude":0.034942,"askPrice":35.26,"askSize":600,"bidPrice":35.2,"bidSize":1000,"shortable":0,"etf":0,"ttmEps":-1.16,"tradingStatus":2,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1782375000000},"marketStatusCode":2,"adr":0,"listingDate":1778601600000,"exchange":"SEHK","adjPreClose":36.06,"openAndCloseTimeList":[[1782351000000,1782360000000],[1782363600000,1782374400000]],"volumeRatio":1.365733,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/07630","defaultTab":"news","newsList":[{"id":"1157701649","title":"IMPACT Therapeutics boosts share capital by 2.30 % through full over-allotment option exercise","url":"https://stock-news.laohu8.com/highlight/detail?id=1157701649","media":"Bulletin Express","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1157701649?lang=en_us&edition=fundamental","pubTime":"2026-06-11 06:23","pubTimestamp":1781130203,"startTime":"0","endTime":"0","summary":"IMPACT Therapeutics, Inc. (IMPACT THERAP-B) reported that the joint global coordinators fully exercised the over-allotment option on 10 June 2026, resulting in the issuance and allotment of 6.30...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1150770934","title":"IMPACT THERAP-B Issues 6.3 Million H Shares Upon Full Exercise of Over-Allotment Option","url":"https://stock-news.laohu8.com/highlight/detail?id=1150770934","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1150770934?lang=en_us&edition=fundamental","pubTime":"2026-06-11 06:16","pubTimestamp":1781129774,"startTime":"0","endTime":"0","summary":"IMPACT THERAP-B (HKEX: 07630) has announced that on June 10, 2026, it issued and allotted 6.2964 million H shares as a result of the full exercise of the over-allotment option.","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179114095","title":"IMPACT Therapeutics Concludes Stabilization; 6.30 Million H Shares Allotted at HK$20.10 Each","url":"https://stock-news.laohu8.com/highlight/detail?id=1179114095","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1179114095?lang=en_us&edition=fundamental","pubTime":"2026-06-08 17:03","pubTimestamp":1780909380,"startTime":"0","endTime":"0","summary":"IMPACT Therapeutics, Inc. (IMPACT Therapeutics) announced the completion of its post-listing stabilization period on 7 June 2026, exactly 30 days after the close of the Hong Kong Public Offering....","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132981482","title":"IMPACT THERAP-B Concludes Stabilization Period with Full Exercise of Over-Allotment Option","url":"https://stock-news.laohu8.com/highlight/detail?id=1132981482","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1132981482?lang=en_us&edition=fundamental","pubTime":"2026-06-08 16:56","pubTimestamp":1780909011,"startTime":"0","endTime":"0","summary":"The stabilization period relating to the company's global offering concluded on Sunday, June 7, 2026, which is the 30th day after the deadline for submitting Hong Kong public offering...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07630","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641172548","title":"Impact Therapeutics Nets HK$120 Million From Full Exercise of IPO Overallotment Option","url":"https://stock-news.laohu8.com/highlight/detail?id=2641172548","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641172548?lang=en_us&edition=fundamental","pubTime":"2026-06-08 09:15","pubTimestamp":1780881354,"startTime":"0","endTime":"0","summary":"Impact Therapeutics  said the overallotment option of its Hong Kong initial public offering was fully exercised on Friday, according to a same-day Hong Kong bourse filing.The Chinese biopharmaceutical company expects to raise about HK$119.5 million in additional net proceeds.The exercise involved the issue of 6.3 million additional H-shares at HK$20.10 each, representing about 15% of the total offer shares initially available under the global offering.Dealings in the overallotment shares are expected to begin on June 10, the filing said.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IPOS","BK4139","LENZ","BK1161","BK4007","BK4539","07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1199847182","title":"IMPACT Therapeutics Raises HK$119.50 Million via Full Exercise of 15% Over-Allotment Option","url":"https://stock-news.laohu8.com/highlight/detail?id=1199847182","media":"Bulletin Express","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1199847182?lang=en_us&edition=fundamental","pubTime":"2026-06-05 21:03","pubTimestamp":1780664606,"startTime":"0","endTime":"0","summary":"IMPACT Therapeutics, Inc. announced that the overall coordinators have fully exercised the 15% over-allotment option linked to the company’s recent Hong Kong IPO. An additional 6.30 million H shares...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1152339070","title":"IMPACT THERAP-B Fully Exercises Over-Allotment Option","url":"https://stock-news.laohu8.com/highlight/detail?id=1152339070","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1152339070?lang=en_us&edition=fundamental","pubTime":"2026-06-05 20:56","pubTimestamp":1780664180,"startTime":"0","endTime":"0","summary":"IMPACT THERAP-B (07630) has announced that the over-allotment option detailed in the prospectus has been fully exercised by the overall coordinators on Friday, June 5, 2026. This action, taken on...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640138154","title":"Transcenta names Hansen Xu non-executive director, Jun Bao independent director","url":"https://stock-news.laohu8.com/highlight/detail?id=2640138154","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640138154?lang=en_us&edition=fundamental","pubTime":"2026-06-04 19:19","pubTimestamp":1780571941,"startTime":"0","endTime":"0","summary":"Transcenta set to add Hansen Xu as non-executive director, pending shareholder vote at a June 30, 2026 AGM.Xu has been an investment manager since 2021, now a vice president at Liyan Enterprise Management Consulting ; previously a BCG consultant.Jun Bao to rejoin as independent non-executive director, also subject to the AGM vote; he previously served on the board from March 2021 to August 2023.Bao is chief business officer at Biotheus since 2022; previously CEO of Impact Therapeutics, with earlier business development roles at GSK and Onyx.Independent directors Kumar Srinivasan and Zhihua Zhang to step down once the appointments take effect; board committee leadership to be reshuffled.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tr","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260604:nNDL7M7ZQ1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","07630","06628"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123127100","title":"IMPACT Therapeutics Sets 25 June 2026 AGM; Shareholders to Vote on 2025 Results, Auditor Re-Appointment and Dual Mandates","url":"https://stock-news.laohu8.com/highlight/detail?id=1123127100","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1123127100?lang=en_us&edition=fundamental","pubTime":"2026-06-03 19:05","pubTimestamp":1780484712,"startTime":"0","endTime":"0","summary":"IMPACT Therapeutics, Inc. has circulated a proxy form ahead of its 2025 Annual General Meeting, scheduled for 10:00 a.m. on Thursday, 25 June 2026, at the Board Room, 27F, New Bund Times Square, 399...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183390771","title":"IMPACT Therapeutics Sets 25 June 2026 AGM; Board Requests 20% Issuance Mandate and 10% H-Share Buy-back Authority","url":"https://stock-news.laohu8.com/highlight/detail?id=1183390771","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1183390771?lang=en_us&edition=fundamental","pubTime":"2026-06-03 18:43","pubTimestamp":1780483434,"startTime":"0","endTime":"0","summary":"IMPACT Therapeutics, Inc. has convened its 2026 Annual General Meeting (AGM) for 10:00 a.m. on 25 June 2026 at the company’s Board Room, 27F, New Bund Times Square, 399 West Haiyang Road, Pudong...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640905626","title":"Impact Therapeutics announces annual shareholder meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2640905626","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640905626?lang=en_us&edition=fundamental","pubTime":"2026-06-03 18:34","pubTimestamp":1780482850,"startTime":"0","endTime":"0","summary":"Impact Therapeutics will hold its annual general meeting in Shanghai on June 25, 2026.Shareholders will vote on the 2025 board work report, the accountant’s report for 2025, and the 2025 profit distribution plan.Other items include re-appointing Ernst & Young as auditor for 2026, proposed amendments to the articles of association.Resolutions also cover a general mandate to issue shares up to 20% of shares in issue, plus a mandate to repurchase up to 10% of H shares.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Impact Therapeutics Inc. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange  , on June 03, 2026, and is solely responsible for the ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260603:nNDL1q597b:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1190630928","title":"IMPACT THERAP-B (07630) to Unveil Phase I/II Trial Results for IMP1734 at 2026 ASCO Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=1190630928","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1190630928?lang=en_us&edition=fundamental","pubTime":"2026-06-01 08:40","pubTimestamp":1780274422,"startTime":"0","endTime":"0","summary":"IMPACT THERAP-B (07630) announced that the latest Phase I/II clinical data for the highly selective PARP1 inhibitor IMP1734 (also known as EIK1003) will be presented in a poster session at the 2026...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07630","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1199921042","title":"IMPACT Therapeutics highlights IMP1734 Phase 1/2 data at ASCO 2026; monotherapy ORR 14.3%, paclitaxel combo ORR 24.5%","url":"https://stock-news.laohu8.com/highlight/detail?id=1199921042","media":"Bulletin Express","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1199921042?lang=en_us&edition=fundamental","pubTime":"2026-06-01 08:23","pubTimestamp":1780273420,"startTime":"0","endTime":"0","summary":"IMPACT Therapeutics, Inc. (IMPACT Therapeutics) released updated Phase 1/2 clinical results for its PARP1-selective inhibitor IMP1734 (EIK1003) during the 2026 American Society of Clinical Oncology...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640890009","title":"Impact Therapeutics says PARP1 inhibitor IMP1734 posts 14.3% ORR in Phase 1/2 monotherapy data at ASCO 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2640890009","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640890009?lang=en_us&edition=fundamental","pubTime":"2026-06-01 08:06","pubTimestamp":1780272383,"startTime":"0","endTime":"0","summary":"Impact Therapeutics presented Phase 1/2 data for PARP1 inhibitor IMP1734 at the 2026 ASCO Annual Meeting.Monotherapy showed early signs of durable tumor shrinkage in heavily pretreated patients, with a generally favorable safety profile.A separate cohort combining IMP1734 with weekly paclitaxel showed antitumor activity despite extensive prior taxane use.The combination produced manageable safety in an advanced-line setting, with severe side effects largely consistent with chemotherapy-driven blood toxicities.Data support a strategy to pair a PARP1-selective inhibitor with cytotoxic chemotherapy, an approach the company framed as difficult with older PARP drugs.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Impact Therapeutics Inc. pu","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260601:nNDLgDcQN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107678797","title":"Stock Track | Impact Therapeutics-B Soars 15.59% Intraday in Strong Rebound After Post-IPO Profit-Taking","url":"https://stock-news.laohu8.com/highlight/detail?id=1107678797","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1107678797?lang=en_us&edition=fundamental","pubTime":"2026-05-22 11:16","pubTimestamp":1779419803,"startTime":"0","endTime":"0","summary":"Impact Therapeutics-B's stock surged 15.59% intraday, staging a significant rebound in the Hong Kong market. The movement represents a recovery following several sessions of profit-taking pressure...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119583328","title":"Movement Alert｜Impact Therapeutics-B Rises 13.17% in Regular Trading, Strong Rebound After Post-IPO Profit-Taking","url":"https://stock-news.laohu8.com/highlight/detail?id=1119583328","media":"Market Focus","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1119583328?lang=en_us&edition=fundamental","pubTime":"2026-05-22 11:14","pubTimestamp":1779419673,"startTime":"0","endTime":"0","summary":"On May 22, Impact Therapeutics-B (07630.HK) rose 13.17% in regular trading, trading at HK$35.68 per share, with trading volume of approximately HK$8.79 million. The stock staged a strong rebound...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1116682247","title":"Stock Track | Impact Therapeutics-B Plummets 5.18% Intraday on Post-IPO Profit-Taking and Weak Fundamentals","url":"https://stock-news.laohu8.com/highlight/detail?id=1116682247","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1116682247?lang=en_us&edition=fundamental","pubTime":"2026-05-21 10:32","pubTimestamp":1779330773,"startTime":"0","endTime":"0","summary":"Impact Therapeutics-B's stock plummeted 5.18% during intraday trading on Thursday.The decline reflects mounting profit-taking pressure following the company's explosive IPO debut. Impact Therapeutics...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162485828","title":"Movement Alert｜Impact Therapeutics-B Falls 5.77% in Regular Trading, Post-IPO Profit-Taking Pressure Emerges After 108% First-Day Surge","url":"https://stock-news.laohu8.com/highlight/detail?id=1162485828","media":"Market Focus","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1162485828?lang=en_us&edition=fundamental","pubTime":"2026-05-21 10:31","pubTimestamp":1779330674,"startTime":"0","endTime":"0","summary":"On May 21, Impact Therapeutics-B (07630.HK) declined 5.77% in regular trading, trading at HK$35.7 per share, with trading volume of approximately HK$5.39 million.The decline reflects mounting...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186114537","title":"IMPACT THERAP-B Surges Nearly 4% in Late Trading as Core Drug Senaparib Secured National Reimbursement Last December","url":"https://stock-news.laohu8.com/highlight/detail?id=1186114537","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1186114537?lang=en_us&edition=fundamental","pubTime":"2026-05-19 15:52","pubTimestamp":1779177169,"startTime":"0","endTime":"0","summary":"IMPACT THERAP-B (07630) rose nearly 4% in late trading. As of press time, the stock was up 3.93% to HK$39.66, with a turnover of HK$13.8225 million. Public information indicates that IMPACT THERAP-B...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","07630","BK4588","VXUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1147308533","title":"Stock Track | Impact Therapeutics-B Soars 6.95% Intraday on Medical Insurance Inclusion and Pipeline Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=1147308533","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1147308533?lang=en_us&edition=fundamental","pubTime":"2026-05-15 09:41","pubTimestamp":1778809313,"startTime":"0","endTime":"0","summary":"IMPACT THERAP-B (stock code: 07630) saw its stock price soar by 6.95% during intraday trading on Friday, extending its strong performance since its recent listing.The surge is attributed to multiple...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["07630"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.impacttherapeutics.com","stockEarnings":[{"period":"1week","weight":-0.043},{"period":"1month","weight":-0.0435},{"period":"3month","weight":0.794},{"period":"ytd","weight":0.794}],"compareEarnings":[{"period":"1week","weight":-0.037},{"period":"1month","weight":-0.0857},{"period":"3month","weight":-0.0581},{"period":"6month","weight":-0.0932},{"period":"1year","weight":-0.0316},{"period":"ytd","weight":-0.0866}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"IMPACT Therapeutics Inc is a China-based company mainly engaged in biotechnology research and commercialization. The Company is in the commercialization stage. The Company is committed to advancing synthetic lethality (SL)-based precision anti-cancer therapies globally. The Company's independently developed core product, senaparib, in China as a 1L maintenance therapy for ovarian cancer (OC). The Company is currently developing product pipeline packages such as PARP1/2, PARP1, ATR, WEE1, PKMYT1/WEE1, DHX9, ATM, USP1, and CHK1/2.","exchange":"SEHK","name":"IMPACT THERAP-B","nameEN":"IMPACT THERAP-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"IMPACT THERAP-B(07630),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest IMPACT THERAP-B(07630) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"IMPACT THERAP-B,07630,IMPACT THERAP-B股票,IMPACT THERAP-B股票老虎,IMPACT THERAP-B股票老虎国际,IMPACT THERAP-B行情,IMPACT THERAP-B股票行情,IMPACT THERAP-B股价,IMPACT THERAP-B股市,IMPACT THERAP-B股票价格,IMPACT THERAP-B股票交易,IMPACT THERAP-B股票购买,IMPACT THERAP-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"IMPACT THERAP-B(07630),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest IMPACT THERAP-B(07630) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}